Adenovirus-derived peptide-major histocompatibility complex class I molecule

Adenovirus-derived peptide-MHC complexes are composite molecular structures in which short peptides, generated from adenoviral proteins, are bound within the peptide-binding groove of host MHC class I molecules (such as HLA-A2). These complexes are presented at the surface of infected (or, rarely, transduced/tumoral) cells and are recognized by T cell receptors, triggering cellular immune responses aimed at clearing the infection. Their formation is central to viral antigen presentation—making them key targets for immunological detection, vaccine development, and novel cell therapy approaches. Structural studies reveal the specificity of TCR-pMHC recognition and highlight the molecular determinants governing immune surveillance and evasion during adenoviral infection[4][6].\n\nThis molecular entity is not a receptor or enzyme; instead, it is an antigen-presenting complex that forms the principal target for adaptive immune recognition during adenovirus infection.

Other names

Adenovirus peptide-MHC complexAdenoviral epitope-MHC I complexAdenovirus peptide-HLA complexAd-derived pMHC

TCR recognition and binding (immune cell activation); Antibody-mediated neutralization (potential for diagnostic or engineered immunotherapy)